Silvercrest Asset Management Group LLC Sells 1,574 Shares of Simulations Plus, Inc. (NASDAQ:SLP)

Silvercrest Asset Management Group LLC lowered its position in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 1.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 159,759 shares of the technology company’s stock after selling 1,574 shares during the quarter. Silvercrest Asset Management Group LLC’s holdings in Simulations Plus were worth $4,456,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in Simulations Plus by 53.6% during the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock valued at $34,000 after acquiring an additional 427 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in Simulations Plus during the fourth quarter valued at $39,000. Tower Research Capital LLC TRC boosted its position in Simulations Plus by 42.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,575 shares of the technology company’s stock valued at $72,000 after acquiring an additional 764 shares during the last quarter. AlphaQuest LLC boosted its position in Simulations Plus by 502.9% during the fourth quarter. AlphaQuest LLC now owns 2,689 shares of the technology company’s stock valued at $75,000 after acquiring an additional 2,243 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in Simulations Plus during the fourth quarter valued at $86,000. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Price Performance

SLP stock opened at $31.33 on Tuesday. Simulations Plus, Inc. has a 1 year low of $23.01 and a 1 year high of $50.98. The stock has a market capitalization of $630.08 million, a PE ratio of 78.33 and a beta of 1.10. The company’s 50-day moving average is $29.15 and its 200-day moving average is $30.31.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.06. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The business had revenue of $22.43 million for the quarter, compared to analysts’ expectations of $21.93 million. During the same quarter last year, the firm earned $0.20 EPS. The firm’s revenue for the quarter was up 22.5% compared to the same quarter last year. On average, analysts anticipate that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on SLP. KeyCorp increased their price objective on shares of Simulations Plus from $32.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, April 16th. StockNews.com raised shares of Simulations Plus from a “sell” rating to a “hold” rating in a research report on Monday, April 28th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.00.

Insider Activity at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $33.51, for a total value of $670,200.00. Following the completion of the sale, the director now owns 3,344,157 shares in the company, valued at approximately $112,062,701.07. This trade represents a 0.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 19.40% of the stock is owned by insiders.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.